skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Refined by: Journal Title: Drugs remove subject: Edema remove subject: Internal Medicine remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Therapeutic Options in Refractory Diabetic Macular Oedema
Therapeutic Options in Refractory Diabetic Macular Oedema
Material Type:
Article 		Add to My Research

Therapeutic Options in Refractory Diabetic Macular Oedema

Drugs (New York, N.Y.), 2017-04, Vol.77 (5), p.481-492 [Peer Reviewed Journal]

Springer International Publishing Switzerland 2017 ;Copyright Springer Science & Business Media Apr 2017 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-017-0704-6 ;PMID: 28197794

Full text available

Citations Cited by
2
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema
Material Type:
Article 		Add to My Research

Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema

Drugs (New York, N.Y.), 2017-04, Vol.77 (5), p.575-583 [Peer Reviewed Journal]

Springer International Publishing Switzerland 2017 ;Copyright Springer Science & Business Media Apr 2017 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-017-0722-4 ;PMID: 28283896

Full text available

Citations Cited by
3
Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema
Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema
Material Type:
Article 		Add to My Research

Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema

Drugs (New York, N.Y.), 2010-11, Vol.70 (16), p.2171-2200 [Peer Reviewed Journal]

Adis Data Information BV 2010 ;2015 INIST-CNRS ;COPYRIGHT 2010 Wolters Kluwer Health, Inc. ;Copyright Wolters Kluwer Health Adis International Nov 2010 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.2165/11538130-000000000-00000 ;PMID: 20964459 ;CODEN: DRUGAY

Full text available

Citations Cited by
4
Faricimab: First Approval
Faricimab: First Approval
Material Type:
Article 		Add to My Research

Faricimab: First Approval

Drugs (New York, N.Y.), 2022-05, Vol.82 (7), p.825-830 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 ;2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. ;Copyright Springer Nature B.V. May 2022 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-022-01713-3 ;PMID: 35474059

Full text available

Citations Cited by
5
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
Material Type:
Article 		Add to My Research

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

Drugs (New York, N.Y.), 2021-06, Vol.81 (9), p.985-1002 [Peer Reviewed Journal]

The Author(s) 2021 ;Copyright Springer Nature B.V. Jun 2021 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-021-01528-8 ;PMID: 33983615

Full text available

Citations Cited by
6
Loncastuximab Tesirine: First Approval
Loncastuximab Tesirine: First Approval
Material Type:
Article 		Add to My Research

Loncastuximab Tesirine: First Approval

Drugs (New York, N.Y.), 2021-07, Vol.81 (10), p.1229-1233 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 ;Copyright Springer Nature B.V. Jul 2021 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-021-01550-w

Full text available

Citations Cited by
7
Ozanimod: First Approval
Ozanimod: First Approval
Material Type:
Article 		Add to My Research

Ozanimod: First Approval

Drugs (New York, N.Y.), 2020-06, Vol.80 (8), p.841-848 [Peer Reviewed Journal]

Springer Nature Switzerland AG 2020 ;Copyright Springer Nature B.V. Jun 2020 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-020-01319-7 ;PMID: 32385738

Full text available

Citations Cited by
8
Brolucizumab: First Approval
Brolucizumab: First Approval
Material Type:
Article 		Add to My Research

Brolucizumab: First Approval

Drugs (New York, N.Y.), 2019-12, Vol.79 (18), p.1997-2000 [Peer Reviewed Journal]

Springer Nature Switzerland AG 2019 ;Copyright Springer Nature B.V. Dec 2019 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-019-01231-9 ;PMID: 31768932

Full text available

Citations Cited by
9
Uveitis Therapy: The Corticosteroid Options
Uveitis Therapy: The Corticosteroid Options
Material Type:
Article 		Add to My Research

Uveitis Therapy: The Corticosteroid Options

Drugs (New York, N.Y.), 2020-06, Vol.80 (8), p.765-773 [Peer Reviewed Journal]

Springer Nature Switzerland AG 2020 ;Copyright Springer Nature B.V. Jun 2020 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-020-01314-y ;PMID: 32350761

Full text available

Citations Cited by
10
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema
Material Type:
Article 		Add to My Research

Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema

Drugs (New York, N.Y.), 2022-09, Vol.82 (13), p.1403-1410 [Peer Reviewed Journal]

Springer Nature 2022. corrected publication 2022 ;Copyright Springer Nature B.V. Sep 2022 ;Springer Nature 2022, corrected publication 2022 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-022-01763-7 ;PMID: 36018461

Full text available

Citations Cited by
11
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
Material Type:
Article 		Add to My Research

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

Drugs (New York, N.Y.), 2021-11, Vol.81 (17), p.2017-2033 [Peer Reviewed Journal]

The Author(s) 2021 ;2021. The Author(s). ;Copyright Springer Nature B.V. Nov 2021 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-021-01624-9 ;PMID: 34724172

Full text available

Citations Cited by
12
Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation
Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation
Material Type:
Article 		Add to My Research

Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation

Drugs (New York, N.Y.), 2020-07, Vol.80 (11), p.1101-1108 [Peer Reviewed Journal]

Springer Nature 2020. corrected publication 2020 ;Copyright Springer Nature B.V. Jul 2020 ;Springer Nature 2020, corrected publication 2020 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-020-01344-6 ;PMID: 32588339

Full text available

Citations Cited by
13
Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval
Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval
Material Type:
Article 		Add to My Research

Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval

Drugs (New York, N.Y.), 2018-12, Vol.78 (18), p.1925-1929 [Peer Reviewed Journal]

Springer Nature Switzerland AG 2018 ;Copyright Springer Nature B.V. Dec 2018 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-018-1016-1 ;PMID: 30465134

Full text available

Citations Cited by
14
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Material Type:
Article 		Add to My Research

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Drugs (New York, N.Y.), 2019-02, Vol.79 (2), p.125-142 [Peer Reviewed Journal]

Springer Nature Switzerland AG 2019 ;Copyright Springer Nature B.V. Feb 2019 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-018-1039-7 ;PMID: 30623348

Full text available

Citations Cited by
15
Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders
Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders
Material Type:
Article 		Add to My Research

Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders

Drugs (New York, N.Y.), 2021-10, Vol.81 (15), p.1731-1749 [Peer Reviewed Journal]

The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 ;2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. ;Copyright Springer Nature B.V. Oct 2021 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-021-01605-y ;PMID: 34586603

Full text available

Citations Cited by
16
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
Material Type:
Article 		Add to My Research

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

Drugs (New York, N.Y.), 2017-10, Vol.77 (16), p.1755-1768 [Peer Reviewed Journal]

The Author(s) 2017 ;Copyright Springer Science & Business Media Oct 2017 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-017-0814-1 ;PMID: 28905255

Full text available

Citations Cited by
17
Ranibizumab: In Macular Oedema Following Retinal Vein Occlusion
Ranibizumab: In Macular Oedema Following Retinal Vein Occlusion
Material Type:
Article 		Add to My Research

Ranibizumab: In Macular Oedema Following Retinal Vein Occlusion

Drugs (New York, N.Y.), 2011-03, Vol.71 (4), p.455-463 [Peer Reviewed Journal]

Adis Data Information BV 2011 ;2015 INIST-CNRS ;COPYRIGHT 2011 Wolters Kluwer Health, Inc. ;Copyright Wolters Kluwer Health Adis International Mar 2011 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.2165/11206900-000000000-00000 ;PMID: 21395358 ;CODEN: DRUGAY

Full text available

Citations Cited by
18
The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis
The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis
Material Type:
Article 		Add to My Research

The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis

Drugs (New York, N.Y.), 2017-03, Vol.77 (3), p.303-311 [Peer Reviewed Journal]

Springer International Publishing Switzerland 2017 ;Copyright Springer Science & Business Media Mar 2017 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-017-0692-6 ;PMID: 28181178

Full text available

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 2010  (1)
  2. 2010 To 2010  (1)
  3. 2011 To 2016  (1)
  4. 2017 To 2018  (5)
  5. After 2018  (11)
  6. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait